INTRODUCTION
control or a direct site of action of the drug at the muscle or fat cell. For several decades sulphonylurea compounds have been widely
To discriminate between direct sites of action of sulphonylurea used as hypoglycaemic agents in the treatment of type II or nondrugs and effects mediated via insulin, experiments in vitro with insulin-dependent diabetes mellitus. These drugs have been isolated cell preparations are of advantage. During the last two shown to act at both pancreatic and extrapancreatic loci [for a decades a large body of evidence has accumulated that review see and Gerich (1989) ]. The initial effects of sulphonylurea agents enhance basal and insulin-stimulated glusulphonylurea administration appear to arise from acute stimucose transport and metabolism in both human and animal lation of the rate of insulin release from the pancreas (Yalow et muscle (Gibson et al., 1980; Rogers et al., 1987; Wang et al., al., 1960) . 1987, 1989 ) and fat cells (Jacobs et al., 1989; Farese et al., 1991) Recently, attention has been focused on the extrapancreatic in vitro. However, the molecular mechanisms for these actions of sulphonylureas, since prolonged drug studies with stimulatory effects of the drugs are unknown. The increased diabetic patients have demonstrated that plasma insulin levels insulin sensitivity in vitro may be caused by a higher number, often return to pretreatment levels even though the binding affinity or tyrosine kinase activity of the insulin receptor. sulphonylurea-induced hypoglycaemic effect persists (Simonson However, the evidence available strongly points toward a postet al., 1970 Lebovitz et al., 1977; Greenfield et al., 1982;  receptor effect (Maloff and Lockwood, 1981; Davidson and Kolterman et al., 1984; Mandarino and Gerich, 1984; Ward Sladen, 1987; Jacobs et al., 1987; Bak et al., 1989) , which would et al. 1985) . Thus these compounds possess the interesting also explain the stimulation of glucose transport in the absence additional property of increasing glucose uptake and utilization of insulin.
in peripheral tissues after prolonged exposure (Feldman and The activation of protein kinase C via a sulphonylurea-induced Lebovitz, 1971) . Similar findings have been reported in studies increase in diacylglycerol during stimulation of basal glucose with animals exposed for prolonged intervals to various transport in cultured myocytes and adipocytes has been suggested sulphonylurea agents (Caren and Corbo, 1957; Putnam et al., (Rogers et al., 1987; Farese et al., 1991; Davidson et al., 1991) . 1981; Hirshman and Horton, 1990) . It remains a matter of One potential source of diacylglycerol may reside in glucosyldebate as to whether the improved insulin sensitivity observed phosphatidylinositol (GPI) membrane anchors of certain plasmaduring studies in vivo is due to improved overall metabolic membrane ectoproteins, since their metabolism in response to Biochem. J.
(1 993) 289, [509] [510] [511] [512] [513] [514] [515] [516] [517] [518] [519] [520] [521] insulin accompanied by release of the protein moiety from the cell surface of adipocytes and myocytes has been observed (Chan et al., 1988; Romero et al., 1988; Lisanti et al., 1989) and correlated with stimulation of glucose metabolism (Romero et al., 1988) . Furthermore, the cleavage products of structurally related free GPI lipids, diacylglycerol and polar phosphoinositolglycan headgroups, activate glucose transport in isolated rat adipocytes presumably by a two-step mechanism (ObermaierKusser et al., 1989; Vogt et al., 1990 ). Therefore we have studied whether degradation of the GPI membrane anchor and membrane release of GPI-proteins are stimulated by sulphonylurea drugs. (25 Ci/mmol) and EN3HANCE was purchased from DuPont-New England Nuclear (Dreieich, Germany); 3T3 fibroblasts clone A31 were obtained from the American Type Culture Collection (CCL 163). Phenylmethanesulphonyl fluoride (PMSF), 3-isobutyl-1-methylxanthine (IBMX), dexamethasone, defatted BSA and phosphatidylcholine were provided from Sigma (Deisenhofen, Germany); Dulbecco's minimal essential medium (DMEM), Hanks buffer, antibiotics and sera for cell culture, pertussis and cholera toxin were from Gibco-BRL (Eggenstein-Leopoldshafen, Germany); Protein A-Sepharose and Nf-(2-aminoethyl)-cAMP-Sepharose were purchased from Pharmacia (Freiburg, Germany); PI-specific phospholipase C (PI-PLC) (Bacillus cereus), cycloheximide, leupeptin and antipain hydrochloride were provided from Boehringer (Mannheim, Germany); pepstatin A was bought from Fluka (Neu-Ulm, Germany); a2-macroglobulin, aminoethylbenzylsulphonylfluoride, silica gel Si6O t.l.c. plates and all other chemicals (highest purity available) were Cell culture Cell culture was performed according to published procedures (Chan et al., 1988; Harrison et al., 1991a, b) . Briefly, 3T3 fibroblasts were seeded at a density of 60 cells/mm2, grown in DMEM containing 25 mM glucose, 10 % fetal calf serum (FCS), 50 units/ml penicillin and 50 ,ug/ml streptomycin sulphate (20 ml of medium per culture flask or 1.5 ml per well of a 24-well culture plate) and maintained in a 10 % CO2-humidified atmosphere at 37 'C. The medium was changed every 2-3 days. Several days after the cells had achieved confluence, differentiation was induced with the same volume of DMEM containing 10 % FCS, 10 jug/ml insulin, 0.25 ,uM dexamethasone, 0.5 mM IBMX, 50 units/ml penicillin and 50 ,tg/ml streptomycin sulphate. After 2 days, the cells were incubated with the same medium without IBMX and dexamethasone for 2 additional days. Subsequently the cells were maintained in DMEM containing 100 FCS and antibiotics. The medium was changed at intervals of 2-3 days. Cells were used 5-10 days after the induction of differentiation. About 80-90 % of these cells expressed the adipocyte phenotype.
MATERIALS AND METHODS
Living cell numbers were determined by counting the Trypan Blue-excluding cells harvested after trypsin treatment (0.1 % trypsin for 10 min at 30 'C) of the cell monolayers by using a haemocytometer.
Cell membrane preparation
Plasma membranes from 3T3 adipocytes were prepared as described by Simpson et al. (1983) with modifications according to James et al. (1989) and Clancy and Czech (1990) . Briefly, cells were grown in culture flasks and incubated in 20 ml of highglucose (25 mM) DMEM containing 10 % FCS and antibiotics with or without agent as indicated at 37°C for the times indicated. Subsequently, the cells were washed once with 25 ml of room temperature phosphate-buffered saline/ 1 mM EDTA/250 mM sucrose and twice with 15 ml of buffer 1 (25 mM Hepes, 1 mM EDTA, 1 mM PMSF, 250 mM sucrose, pH 7.4). The monolayer from one flask was scraped into 50 ml of ice-cold buffer I supplemented with 0.1 mM PMSF and immediately homogenized with 10 strokes of a motor-driven (750 rev./min) Teflon pestle in a 60 ml glass homogenizer (Braun, Melsungen, Germany) . The homogenate was centrifuged (16000 g, 20 min, 4°C). The pellet was resuspended in 10 ml of buffer 11 (20 mM Hepes, 1 mM EDTA, pH 7.4) with a Dounce homogenizer and layered on to 20 ml of a sucrose cushion (1.12 M sucrose in buffer II) and centrifuged (100000 g, 1 h, 4 'C). Plasma membranes were recovered from the top of the sucrose cushion, resuspended in 30 ml of buffer II and collected by centrifugation (30000 g, 30 min, 4°C). The plasma membranes were washed by repetition of the last centrifugation and finally resuspended in buffer II containing 1 mM PMSF at about 2 mg of protein/ml.
Metabolic labelling
The labelling was performed in culture flasks as described by Chan et al. (1988) leucine-free DMEM (see above). Subsequently, the cells were washed three times with 10 ml of Hanks' buffer (pH 7.4)/0.5 Go BSA/1 mM myo-inositol or 1O mM leucine and then for incubation with glimepiride (chase) supplemented with 20 ml of high-glucose DMEM/10 % FCS/0.5 % BSA/0.1 mM myo-inositol or leucine/50 units/ml penicillin/50 g/ml streptomycin sulphate/I mM IBMX/0.1 mM PMSF.
Photoaffinity labelling This was carried out by a method adapted from one used for yeast cells (Muller and Bandlow, 1991a Triton X-114 partitioning This was carried as described by Bordier (1981) with the following modifications: 50,1 of the incubation mixture was added to 1 ml ice-cold Triton X-1 14 (2 %) in 25 mM Tris/HCl (pH 7.4)/ 144 mM NaCl. The mixture was layered on to a cushion of 0.4 ml 250 mM sucrose/25 mM Tris/HCl (pH 7.4) on ice. Phase separation was induced by warming up to 37°C and centrifugation (Microfuge, 2 min). The detergent phase was reextracted twice. The aqueous phases were pooled.
Immunoprecipitation
Immunoprecipitation was performed according to Muller and Bandlow (1991b) with the following modifications. Medium samples (200,u of a supernatant, Microfuge, 2 min) were passed through a Millex GV 0.2 uM filter, subsequently precipitated with 100% (v/v) trichloroacetic acid and dissolved in 50,ul of 10 mM Tris/HCl (pH 8.0)/i mM EDTA/2 % (w/v) SDS. After being heated at 95°C for 5 min and centrifugation (Microfuge, 5 min), the supernatant was supplemented with 1 ml of immunoprecipitation buffer (10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.05 % Triton X-100). Membrane samples (50 ,g protein in buffer II) were adjusted to 2 % SDS and processed as described above. Then 10#1 of a 1:250 dilution of a polyclonal rabbit antiserum against human milk LPL was added. After 12 h at 4°C followed by addition of 50,l of Protein A-Sepharose, the incubation was continued for 2 h. The immunoprecipitates were collected by centrifugation, washed twice with immunoprecipitation buffer, twice with buffer not containing Triton X-I00 and finally dissolved in 60 mM Tris/HCl (pH 6.8)/2 % SDS/5% 2-mercaptoethanol/10% (v/v) Figure 1 ).
Affinity purffication
This was carried out as described (Muller et al., 1992) with the following modifications: 200,ug of solubilized plasma-membrane protein (25 mM Mops/KOH, pH 7.0, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 0.5 % octyl glucoside) or 250 pl of culture medium were applied to a 2 ml column of N6-(2-aminoethyl)-cAMP-Sepharose. The column was washed five times with 25 mM Mops/KOH (pH 7.2)/100 mM sodium citrate/ 150 mM NaCl/2 mM DTT/l mM MgCl2/10% glycerol/I mg/ ml BSA/ 1 mM IBMX and eluted with 2 ml of the same buffer containing 10 mM cAMP. The initial 250,l of the eluate was desalted by centrifugation through a 1 ml column of Sephadex G-25 and then precipitated with 5 % poly(ethylene glycol) 4000.
The precipitates were dissolved in 20 mM Mops/KOH (pH 7.2)/0.5 mM EDTA/0.I mM PMSF/0.5 % octyl glucoside.
Digestion with PLC
The cell monolayer of one well (per 24-well plate) was washed with DMEM and then incubated with 0.5 ml DMEM containing 0.05 or 0.25 unit PI-PLC (Bacillus cereus) (1 unit is defined as 5, mol bovine acetylcholinesterase cleaved/min), 120 mM NaCl, 2 mM EDTA, 5 mM DTT, 0.005 % Triton X-I00 and 0.1 mg/ml phosphatidylcholine for 2 h at 37 'C.
T.I.c. The samples were concentrated by freeze-drying, suspended in water, applied to a silica gel Si6O t.l.c. plate and developed twice in pyridine/ethyl acetate/acetic acid/water (5:5:1:3, by vol.). Radioactive spots were visualized by autoradiography.
Enzyme assays LPL activity was assayed as described (Nilsson-Ehle and Schotz, 1976 ) with a concentrated anhydrous emulsion of [3H]glycerol tri[9, I0(n)-3H]oleate in glycerol stabilized with phosphatidylcholine as substrate. The final concentrations were triolein (7.5 mM), phosphatidylcholine (0.6 mM), BSA (0.75%, w/v), glycerol (10%) and FCS (7.5 %, v/v) in 50 mM Hepes/KOH (pH 7.8). Incubations were carried out in a total volume of 250,1 for 20 min at 37 'C. The activity of 5'-nucleotidase was assayed as described by Avruch and Wallach (1971) with minor modifications. Briefly, the test was performed in a total volume of 1 ml containing 100 mM Tris/HCl (pH 7.4), 20 mM MgCl2 and 0.5 mM [3H]AMP (100 nCi) for 30 min at 37 'C. The reaction was stopped by the addition of 250 mM ZnSO4. Unhydrolysed AMP and protein were precipitated by the addition of 250,l of 0.3 M Ba(OH)2. The adenosine remaining in solution after centrifugation of the sample (Microfuge, 2 min) was counted for radioactivity in 10 ml of scintillation cocktail (Zinsser 361). Adenylate cyclase was measured as described by Salomon et al. (1974) . Lactate dehydrogenase was assayed by a standard spectrophotometric assay (Wroblewski and LaDue, 1955 Rodel et al. (1985) and Muller and Bandlow (1989) KCI, 5mM MgCl2, 1 mM MnCl2, 0.5 mM EDTA, 0.2mM DTT, 1 mM IBMX, 0.1 mM PMSF, 0.1 mM AMP, 0.2% octyl glucoside). About 100 jtg of protein was incubated with 100 nCi [3H]cAMP (about 2 nmol) in the presence or absence of 0.8 mM cAMP in a total volume of 250,ul for 5 min at 4 'C. After addition of 0.5 ml ice-cold saturated (NH4)2SO4, the sample was rapidly filtered through a nitrocellulose filter (Millipore, HAWP, 0.45 uM) under vacuum. The filter was washed three times with 5 ml of washing buffer (25 mM Mes, pH 6.2, 100 mM KCI, 5 mM MgCl2, 1 mM MnCl2, 0.5mM EDTA, 1 mM IBMX, 0.1 mM PMSF, 1 mM AMP), dried at 70 'C and counted for radioactivity in 5 ml of scintillation cocktail (Zinsser 361). Specific cAMP binding was calculated as the difference between radioactivity measured in the absence and presence of 0.8 mM cAMP.
(Figure lb) into their soluble hydrophilic versions as judged by centrifugation and Triton X-1 14 partitioning which correlated with the appearance of anti-CRD immunoreactivity of the solubilized GPI-proteins as demonstrated by immunoprecipitation with anti-CRD antibodies. The epitope recognized by anti-CRD antibodies primarily consists of the inositol 1,2-cyclic monophosphate residue generated by PLC cleavage of the GPI moiety (Zamze et al., 1988) and thus was available only in the lipolytically cleaved (lanes 18, 20, 22 and 24) but not in the intact form of LPL and cAMP-binding ectoprotein (lanes 13-17, 19, 21 and 23) . The immunoprecipitation of the radiolabelled PI-PLCcleaved GPI-proteins by anti-CRD serum was nearly quantitative. Furthermore, up to 75 % of 5'-nucleotidase activity was released from plasma-membrane vesicles after treatment with bacterial PI-PLC in a concentration-dependent manner (results not shown).
We next studied whether treatment of 3T3 adipocytes with the novel sulphonylurea compound, glimepiride, causes an increase (a)
Miscellaneous procedures
Nitrous acid deamination (Muller and Bandlow, 1991a) , extraction from silica gel, elution of proteins from polyacrylamide gels (Muller et al., 1992) , SDS/PAGE using 15 % separating and 5 % stacking gels in the presence of urea (Laemmli, 1970; Muller and Zimmermann, 1987) , fluorography using EN3HANCE (Chamberlain, 1989) , densitometry with an LKB densitometer, protein determination (Popov et al., 1975; Bradford, 1976) and liquid-scintillation counting using scintillation cocktail ASC II (Amersham-Buchler) were performed according to published procedures. RESULTS 3T3-Ll adipocytes contain a number of GPI-anchored plasmamembrane proteins (Chan et al., 1988; Lisanti et al., 1989) . Release of these ectoproteins from the plasma membrane into the culture medium by removal of their GPI membrane anchor has been observed after short-term incubation with insulin (see the Discussion). We asked whether sulphonylurea drugs, which exert certain insulin-like effects on these cells, also mimic membrane release of GPI-proteins.
We studied three proteins for which anchorage at the plasma membrane by a GPI structure has been established, LPL (Chan et al., 1988) , 5'-nucleotidase (Low and Finean, 1978 ) and a novel cAMP-binding ectoprotein (62 kDa). This protein can be detected by photoaffinity labelling with the membrane-impermeable 8-N3-cAMP of intact adipocytes isolated by collagenase digestion under strictly controlled conditions or of 3T3 adipocytes cultured as monolayers but without trypsin treatment (Muller and Bandlow, 1991c; G. Muller and S. Wied, unpublished work) . The presence of a GPI membrane anchor has been demonstrated by its metabolic labelling with typical constituents of this structure. A similar cAMP-binding protein has been identified in the yeast Saccharomyces cerevisiae (Muller and Bandlow, 1991a,b) .
In addition, the anchorage to the membrane by a GPI moiety of the three proteins in the 3T3 adipocytes from the subclone used in this study was confirmed by incubation of intact adipocytes with bacterial PI-PLC (Figure 1 ). This caused a concentration-dependent conversion of the total membranebound amphiphilic LPL ( Figure la) [Glimepiridel (MM) Figure 2 Glimepiride-induced increase in the activity of GPI-proteins in the culture medium (a) Time course. 3T3 adipocytes were incubated in the absence (curve B) or presence of glimepiride (50 ,uM) without (curve A) or with (curve C) cycloheximide (150 ,ug/ml). After different times, portions of the culture medium were withdrawn and the activities of 5'-nucleotidase and LPL as well as cAMP-binding per ml of culture medium were measured. The total activity in the medium of one well was calculated as the percentage of the total activity determined in plasma membranes from the cells of one well at the zero time point in the absence of glimepiride which was set at 100% of initial membrane-bound activity. The corresponding specific activities of the medium samples were as follows: 5'-nucleotidase, 1.7 nmol/min per ml; LPL, 24.3 nmol/min per ml; cAMPbinding, 0.23 pmol/ml. The values represent the means of four different experiments (cell preparations) with triplicate measurements for each. (b) Concentration dependence. 3T3 adipocytes were incubated for 3 h with different concentrations of glimepiride in the absence (curve A) or presence (curve B) of cycloheximide (150,g/ml). Portions of the culture medium were assayed for 5'-nucleotidase, LPL and cAMP-binding. The total activity recovered in the medium was calculated as the percentage of the initial membrane-bound activity as described above. in the activity of the GPI-proteins in the culture medium. For this the cells were incubated with glimepiride for various times before the medium was assayed for LPL, 5'-nucleotidase and cAMP-binding activity. Figure 2(a) shows that the total activities of all three GPI-proteins increased dramatically in the presence of glimepiride, but with different time courses, reached a plateau and, in the case of the LPL and cAMP-binding activity, decreased thereafter, reaching pretreatment levels after 2-4 h of incubation. This may be caused by inactivation (proteolysis) or adsorption to the cell surface (and subsequent endocytosis) of the released proteins. The loss of LPL activity in the presence of 3T3-LI adipocytes is well known (Olivercrona and Semb, 1987 Interestingly, cycloheximide did not affect the initial increase but markedly decreased the maximal activity of the three GPIproteins in the medium (Figure 2a, Subsequently, the culture medium (ME) was removed and concentrated by trichloroacetic acid precipitation (5% trichloroacetic acid, two washes with acetone). The cells were washed and plasma membranes (PM) were prepared. One-half of the culture medium and plasma membranes was partitioned into Triton X-1 14 (det) and aqueous (aq) phases; the other half was left (tot). For identification of LPL, each sample was immunoprecipitated and analysed by SDS/PAGE and fluorography. For visualization of the photoaffinity-labelled cAMP-binding protein each samples was applied directly to the gel. Molecular masses were derived from marker proteins run in parallel on the same gel.
involves both the release from the cell surface, which is independent of protein synthesis, and synthesis and cell-surface expression of the GPI-proteins. The concentration of glimepiride necessary for half-maximal increase in LPL, 5'-nucleotidase and cAMP-binding activity in the medium during the initial cycloheximide-insensitive phase was 7-10 ,tM (Figure 2b) , with a maximal effect at 60-75 ,uM, and is unaffected by cycloheximide. This confirms that the initial increase in GPI-protein activity in the medium originates from preformed molecules and not from proteins synthesized de novo and expressed at the cell surface in response to the drug. However, stimulation of the expression of GPI-protein genes during longterm treatment with sulphonylureas, as has been found for certain glucose-transporter isoforms (Wang et al., 1989; Tordjman et al., 1989) , is not excluded.
If the above hypothesis is true, treatment of cells with glimepiride in the presence of cycloheximide should result in depletion of GPI-proteins at the cell surface. To test this, the total activities of the GPI-proteins in plasma membranes isolated The experiment was carried out as described in the legend to Figure 3 in the absence or presence of glimepiride (50 ,uM) but with various chase times. Culture medium and plasma membranes were subjected to Triton X-1 14 partitioning. The aqueous phase recovered from the culture medium (curve A) and the detergent phase recovered from plasma-membrane samples (curve B) were analysed after immunoprecipitation (LPL) or directly (cAMP-binding protein) by SDS/PAGE and densitometry of the fluorogram. The ratio between the densitometric values for the plasma membrane (amphiphilic version) or culture medium (hydrophilic version) respectively, in the presence or absence of glimepiride, was calculated for each time point. For the zero time point this ratio was set at 1.0 (fraction of initial value of the plasma membrane and medium respectively). Each value represents the means of three different experiments using different cell preparations.
from glimepiride-stimulated 3T3 adipocytes were determined. The method used for the fractionation of the cultured fat cells yielded plasma membranes of sufficient purity, as demonstrated by an up to 10-fold enrichment in the plasma-membrane proteins, adenylate cyclase and Mg2+-ATPase, together with the GPIproteins, and the diminution of mitochondrial and cytosolic proteins (Table 1) . Figure 3(a) shows that, in the absence of cycloheximide, glimepiride provoked an initial rapid decrease in plasma medium activity of each GPI-protein followed by a rapid increase, finally reaching pretreatment or even higher levels. In the absence of glimepiride the specific activities remained constant. However, the presence of cycloheximide caused a prolonged phase of decrease in the plasma-membrane activity and inhibited its recovery. Incubation with cycloheximide alone caused a slight decrease in activity during the entire incubation period, indicating a basal turnover (degradation and/or release) of the GPI-proteins studied. The altered distribution of GPIprotein but not of integral membrane protein activity (Table 1) again emphasizes the selectivity of the sulphonylurea-stimulated releasing process. The drug concentrations required for maximal loss of GPIprotein activity in the plasma membrane were in the range 3-8 ,uM (Figure 3b , thick lines). Cycloheximide had only minor effects (Figure 3b , thin lines) in agreement with the acute effects of glimepiride. However, after long-term incubation with any concentration of glimepiride, pretreatment levels of plasmamembrane activity were measured in the absence of cycloheximide (shown only for 5'-nucleotidase in Figure 3b ), indicating by SDS/PAGE, eluted from sliced gel pieces and dried under N2. The plasma-membrane samples were resuspended in 0.5 ml of 4 M HCI and incubated at 10O°C for 5 h. The total HCI hydrolysates were applied directly on to a t.I.c. plate which was fluorographed (a, lane 1) and scanned for radioactivity (Berthold radioactivity scanner) (b). The radioactivity of the total hydrolysate applied (total) and of the spot co-migrating with the myoinositol marker (a, I) are given (b, I). The medium samples were concentrated by evaporation (speedvac), subjected to nitrous acid deamination (NA) and subsequently precipitated with 5% trichloroacetic acid (4 OC, 1 h, then 10000 g, 5 min, two acetone washes). The pellet was dissolved in scintillation cocktail and counted for radioactivity (b, protein) . The supernatant was neutralized, concentrated by freeze-drying and analysed by t.l.c. and fluorography (a, lanes 2-6). The radioactivity of the spot co-migrating with the myo-inositol phosphate marker (a, IP) was determined by liquid-scintillation counting of the corresponding spot material scraped from the plate (b, IP Under these conditions most of the radioactivity of LPL and cAMP-binding protein was recovered in the inositol residue after total acid hydrolysis of the purified proteins, t.l.c. analysis and fluorography (Figure 6a, lane 1) or liquid-scintillation counting of the material co-migrating with the inositol marker (Figure 6b, HCl treatment) . This is in agreement with the finding that the protein moiety of LPL and cAMP-binding ectoprotein prepared by nitrous acid deamination (which specifically cleaves between the inositol and nonacetylated glucosamine residues) instead of acid hydrolysis and subsequent trichloroacetic acid precipitation contained very little radioactivity (Figure 6b, (1) with cholera toxin (CT, 200 ng/ml) or pertussis toxin (PT, 100 ng/ml) for 20 h before addition of glimepiride, (2) with a2-macroglobulin (MG, 1 mM), 4-(2-aminoethyl)benzylsulphonyl fluoride (ABF, 100 ,uM) or a mixture of leupeptin, pepstatin A and antipain dihydrochloride (each 10 ,tg/ml) for 5 min before addition of glimepiride, or (3) mock-treated for 20 h before glimepiride stimulation, and then incubated in the absence or presence of glimepiride (Gli; 50 ,uM) for 30 min. LPL and cAMP-binding protein in the culture medium and plasma membrane were assayed as described in legend to Figure   1(a) (Table 2) .
To identify the cleavage site of the putative phospholipase that acts during the initial phase of the releasing process, myo-
[x4C]inositol-labelled LPL and cAMP-binding protein were isolated from the culture medium of 3T3 adipocytes after incubation with glimepiride and then subjected to nitrous acid deamination ( Figure 6 ). After precipitation ofthe released protein moiety with trichloroacetic acid, the supernatant was analysed by t.l.c., fluorography (Figure 6a ) and liquid-scintillation counting of the radiolabelled spot material (Figure 6b after incubation with glimepiride may be due to phosphatase action in the culture medium or during isolation of the proteins. The identification of inositol phosphate in the released GPIproteins, as was observed after a control incubation of 3T3 adipocytes with bacterial PI-PLC ( Figure 6a , lane 2), indicates the activation of a GPI-PLC by glimepiride in 3T3 adipocytes. The generation of radiolabelled phosphatidylinositol after incomplete digestion of the GPI-proteins by PI-PLC and glimepiride ( Figure 6a , lanes 2-6) again confirmed the metabolic incorporation of myo-[14C]inositol. Since some bacterial toxins are known to interfere with hormone-stimulated PLC action, we investigated the effect of Bordetella pertussis and Vibrio cholerae toxins on glimepirideinduced release of the GPI-proteins. Pretreatment of 3T3 adipocytes with both toxins did not affect basal or drug-induced specific activities of the LPL or cAMP-binding protein in the plasma membranes or culture medium (Table 2) . Under the same conditions, pertussis toxin blocked the early insulin-stimulated generation of dimyristoylglycerol (results not shown). Thus the release of these GPI-proteins does not seem to be catalysed by PLC which is regulated via pertussis or cholera toxin-sensitive Gproteins.
In addition to sulphonylurea agents, shown in this study, insulin has been reported to stimulate release of several GPIproteins from 3T3-Ll adipocytes by degradation of their GPI membrane anchor 4,see the Discussion). Therefore we were interested in the relationship between the drug-and insulininduced membrane-releasing mechanisms. Cells were incubated with either 5 or 50 ,uM glimepiride in combination with increasing concentrations of insulin (0.1-100 nM) before the medium was assayed for LPL and 5'-nucleotidase (Figure 8 ). Glimepiride at both concentrations caused a significant increase in enzyme activity in the medium compared with insulin stimulation alone (Figure 8 , curve A). At 5 ,uM glimepiride and 1-20 nM insulin, the total release (Figure 8 , curve B) exceeded the sum of the insulin and glimepiride effects alone, indicative of synergistic effects of glimepiride and insulin. At 50 SM glimepiride and insulin below 10 nM, the effects of glimepiride and insulin were additive, and, with insulin above 10 nM, they were non-additive. The synergistic release at low and the non-additive release at high concentrations of glimepiride and insulin represent a first clue that the sulphonylurea drug and insulin use at least one common step for membrane release of GPI-proteins.
Chronic treatment with sulphonylurea drugs has been reported to increase insulin sensitivity in vivo and in vitro (see the Introduction). Therefore we investigated whether long-term incubation of 3T3 adipocytes with glimepiride enhances the insulin-stimulated release of LPL and 5'-nucleotidase (Figure 9 ). To this end, 3T3 adipocytes were incubated with glimepiride (50 ,uM) for 16 h, then washed extensively to remove the drug and already released GPI-proteins and subsequently treated with various concentrations of insulin (Figure 9a ) for 30 min after which the specific activities of LPL and 5'-nucleotidase in the culture medium were assayed. Long-term incubation with glimepiride ( Figure 9a , curve B) resulted in a significant leftwardshift of the dose-response curve for subsequent acute stimulation of membrane release of the GPI-proteins by insulin. The maximal rate of release was not increased significantly. Analogously, long-term treatment with glimepiride increased the sensitivity of the GPI-protein release for glimepiride (Figure 9b 
DISCUSSION
This paper demonstrates that the novel sulphonylurea drug, glimepiride, stimulates the release of three ectoproteins, LPL, 5'-nucleotidase and a 62 kDa cAMP-binding protein, from the plasma membrane of 3T3 adipocytes into the culture medium. This is based on the time-and concentration-dependent increase in the enzyme activity of these proteins in the medium accompanied by a parallel decrease in enzyme activity in the plasma membrane. Furthermore, radiolabelled LPL and cAMPbinding protein are converted from the membrane-bound amphiphilic form into the soluble hydrophilic form during incubation with glimepiride. It is possible that the sulphonylurea-and insulin-dependent releasing mechanisms share some common steps, since at submaximal concentrations the two agents act in a synergistic manner and at higher concentrations they do not exceed a maximal level of release. Up until now, insulin-regulated membrane release of GPI-proteins has been reported for 3T3-LI adipocytes [LPL (Eckel et al., 1978; Spooner et al., 1979; Chan et al., 1988) ; several unidentified proteins (Lisanti et al., 1989) ; 5'-nucleotidase and cAMP-binding ectoprotein (this study)], BC3H1 myocytes [alkaline phosphatase (Romero et al., 1988)] and HepG-2 cells [heparan sulphate proteoglycan (Ishihara et al., 1987) ], for membranes prepared from rat hindquarter muscles after perifusion with insulin [5'-nucleotidase (Klip et al., 1988) ] and for rat osteosarcoma cells after culture in the presence of insulin [alkaline phosphatase (Levy et al., 1984) ].
The retention of myo-inositol phosphate and appearance of anti-CRD cross-reactivity in the soluble GPI-proteins during the initial phase of glimepiride-induced release indicate cleavage of the GPI membrane anchor by GPI-PLC. Degradation of the PI anchor has also been suggested for the insulin-stimulated release of LPL (Chan et al., 1988) . However, the appearance of released (and enzymically active) LPL and cAMP-binding ectoprotein without myo-inositol and anti-CRD immunoreactivity during later stages of incubation hints at additional hydrolytic processing near the GPI attachment site which does not decrease the apparent size of the proteins in SDS/PAGE. These molecules may originate from either membrane-anchored or lipolytically released GPI-proteins. The kinetics of their appearance after a large pool of lipolytically released proteins has accumulated suggests the latter possibility, i.e. two sequential distinct lipolytic and hydrolytic processing events.
The mechanism by which sulphonylurea drugs stimulate the GPI-PLC remains to be elucidated. A sulphonylurea receptor has been described in pancreatic ,-cells and the brain (Kramer et al., 1988) and characterized as a putative component of an ATPdependent K+ channel [for a review see ] which, however, is absent from 3T3-LI adipocytes and BC3Hl and L6 myocytes (Rajan and Boyd, 1988; Cooper et al., 1990; Davidson et al., 1991) . Binding studies indicate the existence also of specific sulphonylurea receptors in isolated rat adipocytes (Martz et al., 1989) . They have not been characterized so far, but may form a component of the signal-transduction cascade through which sulphonylurea drugs activate a GPI-PLC in extrapancreatic insulin-sensitive cells. It is unknown whether this PLC is structurally related to the insulin-stimulated GPI-PLC from rat liver membranes , the only GPI-PLC in mammalian cells described so far.
The functional significance of the regulated release of GPIectoproteins from the plasma membrane remains a matter of speculation. It may represent a means to down-regulate the cell surface expression of these proteins with respect to their turnover or reduced requirement during some physiological situation. Alternatively, the activity of tne GPI-proteins released into the extracellular space per se may be of physiological importance. The functional state and role of solubilized GPI-proteins in extracellular fluids is not completely understood [for a review see Low (1987) and Low and Saltiel (1988) ]. LPL released from parenchymal cells of various tissues moves through the vascular endothelium and binds to the capillary luminal surface where it hydrolyses di-and tri-acylglycerols. The insulin-deficient state (during uncontrolled type I diabetes) is accompanied by low plasma LPL activity and hypertriglyceridaemia (Bagdade et al., 1967) , pointing to a special need for soluble LPL. Although the function of the cAMP-binding ectoproteins, recently identified in lower and higher eukaryotes, is not known, it may be of interest in this respect that the yeast GPI-anchored 54 kDa cAMP-binding ectoprotein, which is structurally related to the cAMP-binding ectoprotein of 3T3 adipocytes, exhibits different cAMP-binding characteristics and an additional amino acid photoaffinity-labelled with 8-N3-[32P]cAMP after cleavage of its GPI membrane anchor with exogenous GPI-PLC from Trypanosoma brucei (G. Muller and W. Bandlow, unpublished work) . This hints at the possibility that the removal of the GPI modification and/or the altered localization may cause changes in the conformation and function of GPI-proteins. A physiological function may also reside in the potential cleavage products of PLC action on the GPI moiety and limited proteolysis at the C-terminus of the GPI-proteins, diacylglycerol and GPI-peptides or phosphoinositolglycan peptides. These molecules may function as chemical mediators for some of the stimulatory effects of sulphonylurea on glucose utilization in isolated rat adipocytes and cultured 3T3-LI adipocytes (Jacobs et al., 1989; Farese et al., 1991) .
Our data imply that the novel sulphonylurea compound, glimepiride, is not only valuable as an oral antidiabetic drug (Geisen, 1988) , but may be useful for elucidation of the mode of action of this class of therapeutic agents in extrapancreatic tissues.
